SCHEMBL184501

SCHEMBL184501

COC(=O)c1cc(C(=O)O)cc(-c2ccc(F)cc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.55
BCL2L1 Q07817 1/20 0.55
BAD Q92934 1/20 0.55
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
PPARA Q07869 1/20 0.47
PTGS1 P23219 1/20 0.47
ATM Q13315 1/20 0.46
SLC6A4 P31645 1/20 0.46
SLC6A3 Q01959 1/20 0.46
DHODH Q02127 1/20 0.46
RXRA P19793 1/20 0.46
ERN1 O75460 1/20 0.46
AURKA O14965 1/20 0.46
TPX2 Q9ULW0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL184208 0.93 KDM4E (0.61) KDM4EBCL2L1BADNPC1RAB9A
SCHEMBL4486670 0.90 KDM4E (0.57) KDM4EBCL2L1BADNPC1RAB9A
SCHEMBL15008457 0.86 RXRA (0.61) KDM4ERXRAERN1EGFRTSHR
SCHEMBL15157461 0.86 BCL2L1 (0.72) KDM4EBCL2L1BADPPARADHODH
SCHEMBL1495508 0.85 DHODH (0.57) KDM4ERAB9AMAPTDHODHRXRA
SCHEMBL3049378 0.85 DHODH (0.59) DHODHLMNAEGFRTSHR
SCHEMBL1544732 0.83 HCAR1 (0.53) KDM4ENPC1RAB9AMEN1KMT2A
SCHEMBL30822018 0.83 HCAR1 (0.53) KDM4ENPC1RAB9AMEN1KMT2A
SCHEMBL18172335 0.83 KDM4E (0.50) KDM4EBCL2L1BADNPC1RAB9A
SCHEMBL4500103 0.83 NOTUM (0.53) KDM4EBCL2L1BADNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501992-B2 Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-06 US disclosed
US-8501992-B2 Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-06 US disclosed
EP-2297103-B1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-01-04 EP disclosed
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-12-01 US disclosed
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-12-01 US disclosed
EP-2297103-A1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS Bristol-Myers Squibb Company (US) 2011-03-23 EP disclosed
WO-2009152082-A1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-17 WO disclosed
WO-2009152082-A1 HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294793-A1 HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS BCL2, BAX, BCL2A1 KDM4E 3403/4885BCL2L1 4/4885BAD 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.